Impairment of stress adaptive behaviours in rats by the CCKA receptor antagonist, devazepide

British Journal of Pharmacology

Volumn 118, Issue 2, 1996, Pages 400-406

  Hernando, Fernando ^a   Fuentes, José A ^a   Ruiz Gayo, Mariano ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

CCK; Depression; Devazepide; Dexamethasone; Forced swimming test; Hippocampus; Hypothalamo pituitary adrenal axis; L 365,260; Stress adaptive behaviours

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CHOLECYSTOKININ OCTAPEPTIDE; DEVAZEPIDE; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR;

ADAPTIVE BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IMMOBILIZATION; MALE; NEUROENDOCRINE SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT; STRESS; SWIMMING;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; BENZODIAZEPINONES; DEVAZEPIDE; DEXAMETHASONE; MALE; PHENYLUREA COMPOUNDS; RATS; RATS, WISTAR; RECEPTOR, CHOLECYSTOKININ A; RECEPTORS, CHOLECYSTOKININ; SINCALIDE;

EID: 0029996087     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15416.x     Document Type: Article

References (38)

1. ARMARIO, A. & CASTELLANOS, J.M. (1984). A simple procedure for direct corticosterone radioimmunoassay in the rat. Rev. Esp. Fisiol., 40, 437-442.
2. BABER, N.S., DOURISH, C.T. & HILL, D.R. (1989). The role of CCK, caerulein, and CCK antagonists in nociception. Pain, 39, 307-328.
3. BRADWEJN, J., KOSZYCKI, D. & SHRIQUL (1991). Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioural findings. Arch. Gen. Psychiatry, 48, 603-610.
4. BRANCHERAU, P., BÖHME, C.A., CHAMPAGNAT, J., MORINSURUN, M.P., DURIEUX, C., BLANCHARD. J.C., ROQUES, B.P. & DENAVIT-SAUBIE, M. (1992). Cholecystokinin A and cholecystokinin B receptors in neurons of the brainstream solitary complex of the rat: pharmacological identification. J. Pharmacol. Exp. Ther., 260, 1433-1440.
5. CALOGERO, A.E., NICOLISI, A.M.G., MONCADA, M.L., CONIGLIONE, F., VICARI, E., POLOSA, P. & D'AGATA, R. (1993). Effects of cholecystokinin octapeptide on the hypothalamic-pituitary-adrenal axis function and on vasopressin, prolactin and growth hormone release in humans. Neuroendocrinology, 58, 71-76.
6. CHANG, R.S. & LOTTI, V.J. (1986). Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc. Natl. Acad. Sci. U.S.A., 83, 4923-4926.
7. CRAWLEY, J.N. (1991). Cholelcystokinin-dopamine interactions. Trends Pharmacol. Sci., 12, 232-235.
8. CRAWLEY, J.N., HAYS, S.E. & PAUL, S.M. (1981). Vagotomy abolishes the inhibitory effects of cholecystokinin on rat exploratory behaviours. Eur. J. Pharmacol., 73, 379-380.
9. CRAWLEY, J.N., HOMMER, L.R. & SKIRBOLL, L.R. (1985). Topographical analysis of nucleus accumbens sites at which cholecystokinin potentiates dopamine-induced hypolocomotion in rats. Brain Res., 335, 337-341.
10. DAUGE, V., DERRIEN, M., BLANCHARD, J.C. & ROQUES, B.P. (1992). The selective CCK-B agonist, BC-264, injected in the antero-lateral part of the nucleus accumbens, reduces the spontaneous alternation behaviour of rats. Neuropharmacology, 31, 67-75.
11. DE KLOET, E.R., DE KOCK, S. & VELDHUIS, H.D (1988). Antiglucocorticoid RU 38486 attenuates and disinhibits the hypothalamic-pituitary adrenal axis at different brain sites. Neuroendocrinology., 47, 109-115.
12. DE MONTIGNY, C. (1989). Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Arch. Gen. Psychiatry, 46, 511-517.
13. B antagonists in mice: antagonism by naltrindole. Br. J. Pharmacol., 111, 956-960.
14. HAMON, M. (1994). Neuropharmacology of anxiety: perspectives and prospects. Trends Pharmacol. Sci., 15, 36-39.
15. HARRO, J., VASAR, E. & BRADWEJN, J. (1993). CCK in animal and human research on anxiety. Trends Pharmacol. Sci., 14, 244-249.
16. HERNANDO, F., FUENTES, J.A., ROQUES, B. & RUIZ-GAYO, M. (1994). The CCK-B receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swimming test in mice. Eur. J. Pharmacol., 261, 257-263.
17. ITOH, S. & KATSUURA, G. (1986). Behavioural effect of cholecystokinin octapeptide in vagotomized rats. Can. J. Physiol. Pharmacol., 64, 745-747.
18. ITOH, S. & LAI, H. (1990). Influences of cholecystokinin and analogues on memory processes. Drug Develop. Res., 21, 257-266.
19. ITOH, S., TAKASHIMA, A. & MAEDA, Y. (1992). Memory impairments induced by peripherally administered cholecystokinin A-type receptor antagonists in rats. Drug Develop. Res., 26, 89-99.
20. KAMILARIS, T.C., JOHNSON, E.O., CALOGERO, A.E., KALOGERAS, K.T., BERNARDINI, R., CHOROUS, G.P. & GOLD, P.W. (1992). Cholecystokinin-octapeptide stimulates hypothalamic-pituitary-adrenal function in rats: Role of corticotropin-releasing hormone. Endocrinology, 130, 1764-1774.
21. KATSUURA, G. & ITOH, S. (1986). Preventive effect of cholecystokinin octapeptide on experimental amnesia in rats. Peptides, 7, 105-110.
22. LOTTI, V.J. & CHANG, R.S.L. (1989). A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand L-365,260. Eur. J. Pharmacol., 162, 273-280.
23. MATSUMURA, M., YAMANOI, A., YAMAMOTO, S. & SAITO, S. (1983). In vivo and in vitro effects of cholecystokinin octapeptide on the release of β-endorphin-like immunoreactivity. Neuroendocrinology, 36, 443-448.
24. MAURICE, T., HIRAMATSU, M., KAMEYAMA, T., HASEGAWA, T. & NABESHIMA, T. (1994). Cholecystokinin-related peptides, after systemic or central administration, prevent carbon monoxide-induced amnesia in mice. J. Pharmacol. Exp. Ther., 269, 665-673.
25. MERANI, S., GUTKOWSKA, J., BRADWEJN, F.R. & ERVIN, F.R. Behavioural effects of CCK-4: Central or peripheral? Society for Neuroscience. 24th Annual Meeting, November 13-18, 1994. Abst. No 163.3.
26. MICHEAU, J., DESTRADE & SOUMIREU-MOURAT, B. (1985). Time-dependent effects of posttraining intrahippocampal injections of corticosterone on retention of repetitive learning tasks in mice. Eur. J. Pharmacol., 106, 39-46.
27. MILLINGTON, W.R., MUELLER, G.P. & LAVIGNE, G. (1992). Cholecystokinin type A and type B receptor antagonists produce opposing effects on cholecystokinin-stimulated β-endorphin secretion from the rat pituitary. J. Pharmacol. Exp. Ther., 612, 454-461.
28. O'NEILL, M.F., DOURISH, C.T. & IVERSEN, S.D. (1991). Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCK-A receptor antagonist devazepide, but not by the CCK-B receptor antagonist L-365,260. Eur. J. Pharmacol., 193, 203-208.
29. PAPOLOS, D.F., EDWARDS, E., MARMUR, R., LACHMAN, H.M. & HENN, F.A. (1993). Effects of the antiglucocorticoid RU 38486 on the induction of learned helpless behaviour in Sprague-Dawley rats. Brain Res., 615, 304-309.
30. PORSOLT, R., ANTON, G., BLAVET, N. & JALFRE, M. (1978). Behavioural despair in rats: A new model sensitive to Antidepressant treatments. Eur. J. Pharmacol., 47, 379-383.
31. RAVARD, S. & DOURISH, C.T. (1990). Cholecystokinin and anxiety. Trends Pharmacol. Sci., 11, 271-273.
32. REISINE, T. & JENSEN, R. (1986). Cholecystokinin-8 stimulates adrenocorticotropin release from anterior pituitary cells. J. Pharmacol. Exp. Ther., 236, 621-626.
33. SIEGEL, R.A., DÜKER, E.-M., FUCHS, E., PAHNKE, U. & WUTTKE, W. (1985). Responsiveness of mesolimbic, mesocortical, septal and hippocampal cholecystokinin and substance P neuronal system to stress, in the male rat. Neurochem. Int., 6, 783-789.
34. SIEGEL, R.A., DÜKER, E-M., PAHNKE, U. & WUTTKE, W. (1987). Stress-induced changes in cholecystokinin and substance P concentrations in discrete regions of the rat hypothalamus. Neuroendocrinology, 46, 75-81.
35. SNEDECOR, G.W. & COCHRAN, W.G (1980). Statistical Methods. 7th Edition. Iowa: The Iowa State University Press.
36. VASAR, E., HARRO, J., LANG, A., POLD, A. & SOOSAAR, A. (1991). Differential involvement of CCK-A and CCK-B receptors in the regulation of locomotor activity in the mouse. Psychopharmacology, 105, 393-399.
37. WILLNER, P. (1990). Animal models of depression: an overview. Pharmacol. Ther., 45, 425-455.
38. WOODS, M.D., SHIPSTON, J., MULLENS, E.L. & ANTONI, F.A. (1992). Pituitary corticotrope tumor (AtT20) cells as a model system for the study of early inhibition by glucocorticoids. Endocrinology, 131, 2873-2880.